Stockscreener 앱 받기
1.01
1.94%
-0.02
시간 외 거래:
1.01
전일 마감가:
$1.03
열려 있는:
$1.03
하루 거래량:
430.78K
Relative Volume:
0.58
시가총액:
$86.39M
수익:
-
순이익/손실:
$-50.21M
주가수익비율:
-0.5301
EPS:
-1.9053
순현금흐름:
$-16.61M
1주 성능:
-2.88%
1개월 성능:
+7.09%
6개월 성능:
-17.89%
1년 성능:
-34.42%
1일 변동 폭
$0.9646
$1.0499
1주일 범위
$0.9486
$1.0499
52주 변동 폭
$0.8641
$2.18
Rein Therapeutics Inc Stock (RNTX) Company Profile
명칭
Rein Therapeutics Inc
전화
(737) 802-1989
주소
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.01 | 88.11M | 0 | -50.21M | -16.61M | -1.9053 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-22 | 개시 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2017-07-24 | 개시 | BofA/Merrill | Buy |
| 2017-07-24 | 개시 | Jefferies | Buy |
| 2017-07-24 | 개시 | William Blair | Outperform |
Rein Therapeutics Inc 주식(RNTX)의 최신 뉴스
Price to earnings forward of Rein Therapeutics, Inc. – BOATS:RNTX - TradingView
Enterprise value to EBIT forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
RNTXRein Therapeutics Inc Latest SEC Filings - Finviz
Rein Therapeutics Inc.(NasdaqCM:RNTX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Rein Therapeutics Inc.(NasdaqCM: RNTX) added to Russell 3000E Value Benchmark - marketscreener.com
Rein Therapeutics, Inc Actuals & Estimates (NASDAQ:RNTX) - TradingView
RNTX Forecast — Price Target — Prediction for 2027 - TradingView
Rein Therapeutics Inc (RNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rein Therapeutics Inc (RNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Narrower‑than‑expected loss as clinical pipeline advances - dars.gov.et
Rein Therapeutics Inc (RNTX) Institutional Confidence - TradingKey
RNTX Q1 2026 Earnings: Strong EPS Beat Driven by Cost Management and Pipeline ProgressProfit Cycle Analysis - dars.gov.et
Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rein Therapeutics Inc (RNTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rein Therapeutics Inc (RNTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rein Therapeutics Inc (RNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rein Therapeutics Inc (RNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rein Therapeutics Inc (RNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy - Yahoo Finance
Rein Therapeutics enrolls 16 patients in lung fibrosis trial By Investing.com - Investing.com Nigeria
Rein Therapeutics (RNTX) Slips 1.6% as Stock Tests Key Support at $0.89Small Cap Breakouts - newsline.com
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock HigherPost-Earnings Reaction - newsline.com
Rein Therapeutics enrolls 16 patients in lung fibrosis trial - Investing.com
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - GlobeNewswire
RNTX Q1 2026 Earnings: Significant EPS Beat Highlights Cost Discipline as Pre-Revenue Biotech Advances PipelineInterim Report - newsline.com
Rein Therapeutics (NASDAQ: RNTX) 2026 proxy outlines share boost, director elections, pay - Stock Titan
RNTX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright cuts Rein Therapeutics stock price target on dilution By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Rein Therapeutics(RNTX.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
12 Health Care Stocks Moving In Monday's After-Market SessionAbivax (NASDAQ:ABVX), Aditxt (NASDAQ:ADTX - Benzinga
Rein Therapeutics (RNTX) Holds Steady at $1.11, Testing Key SupportUpthrust Pattern - dars.gov.et
Rein Therapeutics (RNTX) Holds Steady at $1.11 as Stock Tests Key Support and Resistance LevelsDeath Cross - The Legal Advocate
Rein Therapeutics (RNTX) Holds Steady at $1.11 – Range-Bound Action Points to Key LevelsPCR Mean Reversion - The Legal Advocate
Rein Therapeutics director buys $49,560 in company stock By Investing.com - Investing.com Australia
Rein Therapeutics director buys $49,560 in company stock - Investing.com
Rein Therapeutics (RNTX) asks shareholders to double authorized shares to 200M - Stock Titan
Rein Therapeutics (RNTX) Slips Near Support; Key Levels TestedBackspread Trade - newsline.com
RNTX Q1 2026 Earnings: EPS Beats Estimates as Preclinical Stage Biotech Tightens SpendingAnalyst Consensus Shift - Newser
RNTX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Rein Therapeutics Advances PipelineProfit Growth Outlook - Newser
RNTX Q1 2026 Earnings: Narrower‑than‑expected Loss Fails to Lift SharesEarnings Acceleration Picks - newsline.com
Rein Therapeutics (RNTX) Surges 7% as Stock Tests Key Resistance at $1.09Community Risk Signals - newser.com
Rein Therapeutics (RNTX) Q1 2026 Earnings Surprise: EPS $-0.19, Up SignificantHigh Estimate Range - Newser
Rein Therapeutics closes $57.5 million stock offering By Investing.com - Investing.com Nigeria
Rein Therapeutics announces closing of $57.5 million underwritten public offering - marketscreener.com
Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering - TradingView
Rein Therapeutics closes $57.5 million stock offering - Investing.com
Biotech Rein Therapeutics raises $57.5M for lung fibrosis trial - Stock Titan
Rein Therapeutics, Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements - Minichart
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics, Inc. 1Q 2026: Revenue $0 Net loss $(5.84)M, EPS $(0.19) — 10-Q Summary - TradingView
Rein Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Rein Therapeutics Inc (RNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rein Therapeutics Inc 주식 (RNTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| VON RICKENBACH JOSEF H | Director |
May 22 '26 |
Buy |
1.05 |
15,950 |
16,708 |
34,824 |
| VON RICKENBACH JOSEF H | Director |
May 27 '26 |
Buy |
1.07 |
4,500 |
4,819 |
62,514 |
| VON RICKENBACH JOSEF H | Director |
May 21 '26 |
Buy |
1.04 |
3,420 |
3,564 |
18,874 |
| WINDSOR JAMES BRIAN | See Remarks |
Apr 30 '26 |
Buy |
1.00 |
25,000 |
25,000 |
27,046 |
| Voss Capital, LP | 10% Owner |
Nov 14 '25 |
Buy |
1.22 |
104,183 |
127,593 |
926,441 |
| Voss Capital, LP | 10% Owner |
Oct 28 '25 |
Buy |
1.39 |
178,392 |
247,965 |
500,000 |
| Voss Capital, LP | 10% Owner |
Oct 27 '25 |
Buy |
1.37 |
97,482 |
133,544 |
822,258 |
| Voss Capital, LP | 10% Owner |
Oct 24 '25 |
Buy |
1.39 |
30,176 |
41,957 |
729,616 |
1.17%
2.48%
자본화:
|
볼륨(24시간):